LCS
ACHL

Levin Capital Strategies’s Achilles Therapeutics ACHL Stock Holding History

Levin Capital Strategies’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,000
Closed -$166K – 413
2021
Q1 		$166K Buy
+10,000
New +$166K 0.02% 265

Other funds holding ACHL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Levin Capital Strategies's ACHL Position: Q2 2021 in Review

Levin Capital Strategies sold out of Achilles Therapeutics (ACHL) in Q2 2021, closing a stake of 10,000 shares — an estimated $166K sold.

Levin Capital Strategies first reported a position in ACHL in Q1 2021 and held it in 1 quarter. The position peaked at $166K in Q1 2021. 29 funds tracked by Wall St. Rank hold ACHL as of Q2 2021.

  • Levin Capital Strategies reported no remaining Achilles Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Levin Capital Strategies sold 10,000 Achilles Therapeutics shares in Q2 2021, an estimated $166K.
  • Levin Capital Strategies first reported a position in Achilles Therapeutics in Q1 2021 and held it in 1 quarter.
  • Levin Capital Strategies's Achilles Therapeutics position peaked at $166K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2021.

Based on Levin Capital Strategies's 13F filing for Q2 2021, filed 11 Aug 2021.